The effects of mosquito saliva on dengue virus infectivity in humans.
Sineewanlaya Wichit, Pauline Ferraris, Valérie Choumet, Dorothée Missé

To cite this version:
Sineewanlaya Wichit, Pauline Ferraris, Valérie Choumet, Dorothée Missé. The effects of mosquito saliva on dengue virus infectivity in humans. Current Opinion in Virology, 2016, 21, pp.139-145. 10.1016/j.coviro.2016.10.001. pasteur-01453403

HAL Id: pasteur-01453403
https://pasteur.hal.science/pasteur-01453403
Submitted on 16 Mar 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License
The effects of mosquito saliva on dengue virus infectivity in humans
Sineewanlaya Wichit¹, Pauline Ferraris¹, Valérie Choumet² and Dorothée Missé¹

Arboviruses such as Dengue, Chikungunya, and Zika viruses represent a major public health problem due to globalization and propagation of susceptible vectors worldwide. Arthropod vector-derived salivary factors have the capacity to modulate human cells function by enhancing or suppressing viral replication and, therefore, modify the establishment of local and systemic viral infection. Here, we discuss how mosquito saliva may interfere with Dengue virus (DENV) infection in humans. Identification of saliva factors that enhance infectivity will allow the production of vector-based vaccines and therapeutics that would interfere with viral transmission by targeting arthropod saliva components. Understanding the role of salivary proteins in DENV transmission will provide tools to control not only Dengue but also other arboviral diseases transmitted by the same vectors.

Addresses
¹ Laboratory of MIVEGEC, UMR 224 IRD/CNRS/UM1, Montpellier, France
² Environment and Infectious Risks Unit, Pasteur Institute, Paris, France

Corresponding author: Missé, Dorothée (dorothée.misse@ird.fr)

Introduction
Mosquitoes are blood-feeding arthropods and, therefore, vectors of causative agents of important emerging infectious diseases. They are able to transmit several types of micro-organisms associated with vector borne disease, that cause more than 1 million deaths each year (WHO, 2016). Dengue virus (DENV) is the most important arbovirus in humans, infecting about 390 million individuals globally, with up to 96 million symptomatic infections. DENV infection results in a spectrum of illnesses, ranging from a flu-like disease (dengue fever) to dengue hemorrhagic fever (DHF) that can progress to dengue shock syndrome (DSS) and death. There are over 500 000 cases of DHF/DSS reported worldwide each year, 25 000 of which lead to death, mostly among young children under the age of 15 [1]. Epidemics with a high frequency of DHF/DSS continue to expand geographically in Asia and South America, highlighting the need to control the spread of this disease [2]. To date, there are no vaccines or effective treatments available for DENV infection.

DENV is a single-stranded RNA virus belonging to the Flaviviridae family. The four dengue serotypes (DENV-1 to DENV-4) are transmitted to humans by the Aedes (Ae.) mosquitoes species (Ae. aegypti and Ae. albopictus), which are spreading throughout the world due to climate change and globalization [3]. A dramatic increase in urbanization has also created ideal conditions for increased transmission of mosquito-borne dengue disease. Outbreaks of DENV have generally been restricted to resource-limited areas of tropical and subtropical latitudes, in which 40% of the global population live. However, due to the increasing range of the DENV vectors, the virus could spread outside of these regions [4].

Understanding the transmission cycle of DENV is important for the control of the spread of this disease. The cycle is initiated when pathogen-containing fluids are ingested by the vector from an infected vertebrate during a blood meal. Once the virus crosses the midgut barrier and has replicated in the mosquito, it reaches the salivary glands which leads to high levels of viral titers in the saliva of infected arthropods [5-7]. An infected mosquito will then transmit the virus to a host by delivering most of the viral content through the saliva into both the epidermis and dermis where resident and migratory cells encounter the pathogen [8**].

Though it is known that the DENV contained in salivary glands is closely associated with mosquito saliva, little is known about the function of the Aedes mosquito’s salivary proteins and their role in the transmission of the virus.

Mosquito saliva helps to successfully obtain a blood meal [9] and could also contribute to an optimal transmission of the pathogen by modulating the host immune response [10]. It is as yet unknown, however, how salivary proteins may affect the human immune system during the transmission of the virus.

This review will summarize the effect of mosquito saliva and salivary proteins on the transmission of DENV in humans.
Human innate immune response against DENV

Human skin cells represent the first physical and immunological barrier after being infected by DENV through a mosquito bite [8**]. Skin cells may contribute to the pro-inflammatory and antiviral microenvironment that is established in the early stages of DENV infection. Pattern recognition receptors (PRRs) such as membrane-bound toll like receptors (TLRs), cytoplasmic helicases (retinoic-acid-inducible gene I (RIG-I) and melanoma differentiation-associated gene 5 (MDA5)) and protein kinase R (PKR) are the first lines of defense in the immune recognition of DENV [11–13]. These PRRs trigger signaling cascades that induce the activation of transcription factors including interferon regulatory factors (IRF3 and IRF7). This will lead to the production of type I interferons (IFN-α/β) resulting in the expression of hundreds of interferon-stimulated genes (ISGs) with various levels of antiviral activity [14]. TLR3, RIG-I, MDA-5 and PKR are induced during DENV infection as well [15]. DENV infection of human fibroblasts and keratinocytes induces the production of antimicrobial peptides such as LL37, β-defensin, RNase 7 and S100 family members, that are essential components of the innate immune response (Figure 1) [16,17]. Dendritic cells (DCs) are sentinels of the immune system that

Figure 1

Schematic representation of the impact of Aedes aegypti saliva on the human antiviral response to DENV. DENV infection of human epidermal keratinocytes in the presence of Aedes aegypti mosquito saliva affects the immune response by decreasing the production of type I interferons (IFN-α/β), the transcriptional regulation of IRF3 and IRF7 and the expression of the antimicrobial peptides β-defensin, LL37 and Elafin which increases viral replication. Concurrently, the presence of saliva during DENV infection of human DCs enhances the production of IL-12p70 and TNF-α, resulting in a decrease of viral replication.
detect pathogens at sites of entry such as the skin. Following this initial contact with the virus, DCs mature and migrate to the draining lymph nodes, becoming effective stimulators of T cell responses [18]. In addition to the ability of DCs to control infections directly via their innate immune functions, these cells can also become infected [19]. Hence, DENV was shown to infect epidermal Langerhans cells (LCs) in healthy human skin explants in vitro [20,21]. Another cell type that plays an important role in host defense against viruses through its capacity to modulate both innate and adaptive immune responses is the mast cell [22–24]. Following infection with DENV mast cells have been shown to produce a spectrum of chemokines that are important for the trafficking of natural killer cells, monocytes and T cells [25]. The RNA interference (RNAi) pathway has also been shown to exert antiviral activity against DENV. The knockdown of Dicer, Drosha, Arg01, and Arg02 proteins of the RNAi pathway during DENV infection of mammalian cells results in increased DENV replication [26]. However, DENV has developed several ways to directly inhibit cellular signaling cascades by evading innate antiviral responses [27].

Modulation of vertebrate immune response by mosquito saliva

It has been shown in the literature that mosquito saliva is able to modify the host immune response, although the underlying molecular mechanisms are unclear as yet. Results from initial studies, carried out with C3H/HeJ mice on which Ae. aegypti fed for a blood meal, showed a significant down regulation of IFN-γ production while that of (interleukin (IL) IL-4 and IL-10) was up-regulated [28]. Further studies explored the effect of Aedes saliva or salivary proteins on the transmission of arboviruses. One study reported that viral replication of Rift Valley Fever Virus, as well as the pathogenesis associated with infection with this virus was strongly enhanced by factors contained in saliva and salivary gland extract (SGE) of Aedes mosquitoes [29]. Similarly, in the context of DENV infection, co-infection with A. aegypti saliva, saliva proteins or SGE was also reported to boost viral replication [17,30,31**;32**,33*].

Pathological investigation in fatal human cases revealed spleens with significant destruction of the germinal centers and atrophy of lymphoid follicles, which may be associated with a decrease in the frequency of T cells [34]. Infection of AG129 mice with dengue serotypes triggered gross pathology and histopathological changes in spleens [35]. And in a study using murine splenocytes, a reduction of T-cell and splenocyte proliferation as well as cytokine production (Th1 (IFN-γ) and Th2 (IL-10)) was observed in the presence of Aedes SGE [36]. Production of IFN-γ was also observed in inbred A/J mice infected intravenously with DENV-2 [37]. The effects of Ae. aegypti saliva on DENV infection in human keratinocytes have also been investigated. Both the saliva and recombinant saliva proteins were associated with an increase of mRNA level in the cells and a decrease of type I IFNs, IRF-3 and IRF-7 (Figure 1) [17,31**].

It has furthermore been shown that SGE of Ae. aegypti inhibits the release of tumor necrosis factor alpha (TNF-α) from rat mast cells, but has no effect on antigen-induced histamine secretion [38]. A previous study demonstrated that Ae. aegypti SGE also does not affect the viability of a fetal skin-derived DC line, nor the production of IL-12 by these cells [39]. Consequently, Ae. aegypti SGE has no effect on the basal expression of IFN-β by DCs, but instead decreases the production of this cytokine in West Nile virus-infected cells [40]. There is reportedly no effect of Ae. aegypti SGE on the maturation and function of mice dendritic cells [41]. On the other hand, Ades et al. found that Ae. aegypti saliva had an effect on myeloid DCs by inhibiting their susceptibility to infection by DENV and by enhancing their production of both IL-12p70 and TNF-α (Figure 1). Moreover, pre-sensitization of DCs with saliva prior to infection enhanced inhibition of DENV replication [42]. Variations in the results of these two observations may thus be due to the origin of the DCs, that is, whether they belong to the mouse or human lineage. Together, these observations suggest that Ae. aegypti saliva is involved in the regulation of both innate and adaptive immunity in vertebrate hosts.

Aedes mosquito saliva proteins involved in DENV infectivity

Since Ae. aegypti saliva can affect the transmission and the establishment of arboviruses in humans [8**, much effort has been devoted to characterize the sialome and sialotranscriptome of this vector [43]. The salivary gland protein profile from the Ae. aegypti mosquito was evaluated using a proteomic approach and approximately one hundred proteins were identified in this organ [44]. Ae. aegypti saliva contains many pharmacologically active proteins that can facilitate blood feeding, pathogen transmission and modulate host immune responses [45–47] (Table 1). A functional genomic and proteomic analysis of salivary glands of Ae. aegypti mosquitoes, identified four proteins that strongly enhance DENV replication in human keratinocytes: serpin-like protein (AT), adenosine deaminase (AD), a serine protease with a MW of 34 kDa and a putative secreted protein (VA) [31**]. All of these proteins have been shown to down regulate the expression of IRF-7, but only the 34 kDa protein was able to inhibit the transcriptional expression of IRF-3, resulting in a stronger abrogation of type I IFN production [31**]. These results are in line with a study showing that the combined action of IRF-3 and IRF-7 is required for efficient control of viral replication [14]. The mechanisms by which AT, AD and VA increase DENV infection in keratinocytes have not yet been studied. The 34 kDa
The identification of proteins in *Aedes aegypti* and *Aedes albopictus* saliva can provide insights into viral interactions. Table 1 summarizes the identified proteins:

| Name family          | Gene Bank accession number | Activity                  | DENV infectivity | Immunomodulation | Reference          |
|----------------------|----------------------------|---------------------------|------------------|------------------|--------------------|
| **Apyrase**           |                            |                           |                  |                  |                    |
| 68 kDa AD             | AAEL006347                 | Hydrolase                 | ND               | ND               | [46,47,56]         |
|                      | AAEL005672                 | Adenosine deaminase       | Enhanced         | Suppressed IRF7, IFN type-I and AMP | [31**,47,56] |
| **D7**               |                            |                           |                  |                  |                    |
| D7L1                 | AAEL006417                 | Odorant binding           | ND               | ND               | [56]               |
| D7s2                 | AAEL006423                 | Odorant binding           | ND               | ND               | [44,51,56]         |
| D7L2/37kDa           | AAEL006424                 | Odorant and biogenic amines binding | ND               | ND               | [44,46,51]         |
| **Serine protease**  |                            |                           |                  |                  |                    |
| 34 kDa               | Q1HRW0_AEDAE               | Serine protease           | Enhanced         | Suppressed IRF7, IFN type-I and AMP | [47,31**,47,51] |
| CLIPA3               | AAEL005718                 | Serine-type endonuclease  | Enhanced         | Not changed Th1 and Th2 expression | [48] |
| **Aegyptin**         |                            |                           |                  |                  |                    |
| 30 kDa salivary gland allergen | AAEL010235 | Collagen binding         | Inhibited        | Increased GM-CSF, IFN-γ, IL-5, and IL-6 | [32**,44,46,47,49] |
| Aed a 3              |                            |                           |                  |                  |                    |
| **Serpin-like protein** |                        |                           |                  |                  |                    |
| serpin-4             | AAEL02704                  | Serine protease inhibitor | ND               | ND               | [44]               |
| SRPN2B               | AAEL003182                 | ND                        | ND               | ND               | [56]               |
| Antithrombin (AT)    | Q1HRTV7_AEDAE              | Thrombin inhibitor        | Enhanced         | Suppressed IRF7, IFN type-I and AMP | [31**,47,44] |
| **Vitellogenin-B**   | AAQ92367                   | Lipid transporter         | ND               | ND               | [44]               |
| Vitellogenin-C       | AAQ92366                   | Lipid transporter         | ND               | ND               | [44]               |
| SGS1                 | AAV28546                   | ND                        | ND               | ND               | [44,47]            |
| 34 kDa               | AAL76018, Q8T9V1_AEDAE     | ND                        | ND               | ND               | [44,47]            |
| Venom Allergen (VA)  | Q8T9U5_AEDAE               | ND                        | Enhanced         | Suppressed IRF7, IFN type-I and AMP | [31**]         |
| **Cecropin**         |                            |                           |                  |                  |                    |
| 3.8 kDa              | AAEL000598                 | Antibacterial activities  | Inhibited        | ND               | [5,56]             |
| Sialokinin           | AAEL000229                 | Vasodilatory              | ND               | ND               | [28,56]            |

ND: not determined.

The identification of these proteins suggests that the immune response [32**]. Reducing the abundance of *Aegyptin* through transgene-mediated dsRNA interference results in prolonged probing time and less successful uptake of a blood meal [50*]. It has also been shown that a cecropin-like peptide in the salivary glands of *Ae. aegypti* decreased DENV infectivity in the C6/36 *Ae. albopictus* cell line [5].

Among the proteins up-regulated in DENV infected *Ae. aegypti* SGE, D7 proteins were shown to inhibit platelet aggregation, vaso-constriction and inflammation [51]. A 36 kDa member of the D7 protein family was found to be associated with dengue disease severity [46]. The role of D7 proteins in DENV transmission, however, remains largely unknown. Another major protein found in *Ae. aegypti* saliva, Apyrase, which inhibits ADP-dependent platelet aggregation during blood-feeding and prevents neutrophils activation [52], has also been largely uncharacterized in its role in DENV infection. SAAG-4 protein and sialokinin demonstrated the capacity to modulate the...
ratio of Th1/Th2 cytokine production by suppressing and simultaneously enhancing the expression of IFN-γ and IL-4, respectively, outside the context of viral infection [28,53]. The role of these proteins in DENV transmission remains to be studied.

Table 1 provides a list of saliva proteins that were identified in several studies. However, further investigation is needed to better understand their effect on the DENV infectivity in humans. It is of note that, even if all major epidemics of DHF have occurred only in areas where Ae. aegypti is found, Ae. albopictus is also a competent vector for DENV and has the ability to adapt to diverse environmental conditions in both tropical and temperate regions [54]. To date, there have been no studies on the effect of salivary proteins of this vector in the transmission of DENV.

**Conclusion**

Arboviral diseases have become a great concern due to the expanding geographical range of many mosquito species. Unpredictable outbreaks of arboviral diseases, such as the recent expansion of ZIKA virus, highlight the need to control the spread of their vectors. DENV is arguably the most important arbovirus causing disease in the world today, and despite decades of research, a vaccine is not yet available. Increased understanding of the activity of saliva proteins on DENV infectivity could provide novel targets that may aid in the development of vector-protein based vaccines and therapeutics.

**Acknowledgements**

We thank Dr Hans Yssel for critical discussions and Thanyakorn Rongsawat for technical assistance. This work was supported by grants from the Agence Nationale de la Recherche France (grants ANR-12-BSV3-0004-01 and ANR-14-CE14-0029). Sineewanluya Wicht was supported by a fellowship from the Infectiopôle Sud foundation.

**References and recommended reading**

Papers of particular interest, published within the period of review, have been highlighted as:
- of special interest
- of outstanding interest

1. Bhatt S, Getung PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O et al.: The global distribution and burden of dengue. Nature 2013, 496:504-507.
2. Guzman MG, Halstead SB, Artoib H, Buchy P, Farrar J, Gubler DJ, Hunsperger E, Kroeger A, Margolis HS, Martinez E et al.: Dengue: a continuing global threat. Nat Rev Microbiol 2010, 8:S7-S16.
3. Gubler DJ: Dengue, urbanization and globalization: the unholy trinity of the 21st century. Trop Med Health 2011, 39:3-11.
4. da Silva-Voorham JM, Tami A, Juliana AE, Rodenhuis-Zybert IA, Wilschut JC, Smit JM: [Dengue: a growing risk to travellers to tropical and sub-tropical regions]. Ned Tijdschr Geneeskd 2009, 153:A778.
5. Lupertlop N, Surasombatpattana P, Patramool S, Dumas E, Wasinpiyamongkol L, Saune L, Hamel R, Bernard E, Sereno D, Thomas F et al.: Induction of a peptide with activity against a broad spectrum of pathogens in the Aedes aegypti salivary gland, following Infection with Dengue Virus. PLoS Pathog 2011, 7:e1001252.
6. Salazar MI, Richardson JH, Sánchez-Vargas I, Olson KE, Beaty BJ: Dengue virus type 2 replication and tropisms in orally infected Aedes aegypti mosquitoes. BMC Microbiol 2007, 7:9.
7. Vazeille M, Mousson L, Martin E, Failloux AB: Orally co-infected Aedes albopictus from La Reunion Island, Indian Ocean, can deliver both dengue and chikungunya infectious viral particles in their saliva. PLoS Negl Trop Dis 2010, 4:e706.
8. Briant L, Després P, Choumet V, Missé D: Role of skin immune cells on the host susceptibility to mosquito-borne viruses. Virology 2014, 464-465:26-32.

This review describes the nature of the cells targeted by arboviruses at the skin level and discusses the types of cellular responses elicited by these pathogens.

9. Ribeiro JM: Blood-feeding arthropods: live syringes or invertebrate pharmacologists? Infect Agents Dis 1995, 4:143-152.
10. Valenzuela JG: High-throughput approaches to study salivary proteins and genes from vectors of disease. Insect Biochem Mol Biol 2002, 32:1199-1209.
11. Tsai YT, Chang SY, Lee CN, Kao CL: Human TLR3 recognizes dengue virus and modulates viral replication in vitro. Cell Microbiol 2009, 11:604-615.
12. Loo YM, Fornek J, Crochet N, Bajwa G, Perwitasari O, Martinez-Sobrido L, Akira S, Gill MA, Garcia-Sastre A, Katze MG et al.: Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J Virol 2008, 82:335-345.
13. Nasirudeen AM, Wong HHI, Thien P, Xu S, Lam KP, Liu DX: RIG-4, MDA5 and TLR3 synergistically play an important role in restriction of dengue virus infection. PLoS Negl Trop Dis 2011, 5:e926.
14. Chen HW, King K, Tu J, Sanchez M, Luster AD, Shresta S: The roles of IRF-3 and IRF-7 in innate antiviral immunity against dengue virus. J Immunol 2013, 191:4184-4201.
15. Surasombatpattana P, Hamel R, Patramool S, Lupertlop N, Thomas F, Després P, Briant L, Yssel H, Missé D: Dengue virus replication in infected human keratinocytes leads to activation of antiviral innate immune responses. Infect Genet Evol 2011, 11:1664-1673.
16. Bustos-Ariaga J, García-Machorro J, León-Juárez M, García-Cadero J, Santos-Argumedo L, Flores-Romo L, Méndez-Cruz AR, Juárez-Delgado FJ, Cedillo-Barrón L: Activation of the innate immune response against DENV in normal non-transformed human fibroblasts. PLoS Negl Trop Dis 2011, 5:e1420.
17. Surasombatpattana P, Patramool S, Lupertlop N, Yssel H, Missé D: Aedes aegypti saliva enhances dengue virus infection of human keratinocytes by suppressing innate immune responses. J Invest Dermatol 2012, 132:2103-2105.
18. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
19. Navarro-Sanchez E, Altmeyer R, Amara A, Schwartz Q, Fieschi F, Virelizier J-L, Arenzana-Seisdedos F, Després P: Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep 2003, 4:723-729.
20. Wu SJ, Grouard-Vogel G, Sun W, Mascola JR, Brachet E, Puthatana R, Louder MK, Filgueira L, Marovich MA, Wong HK et al.: Human skin Langerhans cells are targets of dengue virus infection. Nat Med 2000, 6:816-820.
21. Limon-Flores AY, Perez-Tapia M, Estrada-Garcia I, Vaughan G, Escobar-Gutierrez A, Calderon-Amador J, Herrera-Rodriguez SE, Brizuela-Garcia A, Heras-Chavarria M, Flores-Langarica A et al.: Dengue virus inoculation to human skin explants: an effective approach to assess in situ the early infection and the effects on cutaneous dendritic cells. Int J Exp Pathol 2005, 86:323-334.
22. Galli SJ, Maurer M, Lantcz CS: Mast cells as sentinels of innate immunity. Curr Opin Immunol 1999, 11:53-59.
23. Abraham SN, Malaviya R: Mast cells in infection and immunity. Infect Immun 1997, 65:3501-3508.

24. Henn BM, Maurer M, Lippert U, Wurm M, Babina M: Mast cells as initiators of immunity and host defense. Exp Dermatol 2001, 10:1-10.

25. Brown MG, McApline SM, Huang YY, Haidi ID, Al-Afit A, Marshall JS, Anderson R: RNA sensors enable human mast cell anti-viral chemokine production and IFN-mediated protection in response to antibody-enhanced dengue virus infection. PLoS One 2012, 7:e34055.

26. Kakumani PK, Ponia SS, S RK, Sood V, Chinnappan M, Banerjee AC, Medigeshi GR, Malhotra P, Mukherjee SK, Bhattacharjee RK: Aedes aegypti saliva modulates Rift Valley fever virus pathogenicity. PLoS Negl Trop Dis 2013, 7:e2237.

27. Green AM, Beatty PR, Hadjianou A, Harris E: Innate immunity to dengue virus infection and subversion of antifungal responses. J Mol Biol 2014, 428:1148-1160.

28. Zeidner NS, Higgs S, Hopp CM, Beatty BJ, Miller BR: Mosquito feeding modules Th1 and Th2 cytokines in flavivirus susceptible mice: an effect mimicked by injection of sialagogues, but not demonstrated in flavivirus resistant mice. Parasite Immunol 1999, 21:35-44.

29. Le Coupanc A, Babin D, Fierte L, Jouvin G, Ave P, Missa D, Bouley M, Choumet V: Aedes mosquito saliva modulates Rift Valley fever virus pathogenicity. PLoS Negl Trop Dis 2013, 7:e2237.

30. Cox J, Mota J, Sukupolvi-Petty S, Diamond MS, Rico-Hesse R: Mosquito bite delivery of dengue virus enhances immunogenicity and pathogenesis in humanized mice. J Virol 2012, 86:7637-7647.

31. Surasombatpattana P, Ekkachaiyawat P, Hamel R, Patramool S, Thongprungkliat S, Denizot D, Delaunay P, Thomas F, Luplertop N, Yssel H et al.: Aedes aegypti saliva contains a prominent 34-kDa protein that strongly enhances dengue virus replication in human keratinocytes. J Invest Dermatol 2014, 134:281-284.

32. McCracken MK, Christoferson RC, Graspeberg BJ, Calvo E, Chisenhall DM, Mores CN: Aedes aegypti saliva protein “aegyptin” co-inoculation modulates dengue virus infection in the vertebrate host. Virology 2014, 468-470:133-139.

33. Examination of the influence of aegyptin on DENV infection of the vertebrates, using IFI-37”-treated mice with DENV serotype 2 strain 1232 with and without co-inoculation of aegyptin, the data suggest that aegyptin impacts DENV propagation through elevated abundance of the immune response.

34. Schmid MA, Glasner DR, Shah S, Michmayr D, Kramer LD, Harris E: Mosquito saliva increases endothelial permeability in the skin, immune cell migration, and dengue pathogenesis during antibody-dependent enhancement. PLoS Pathog 2016, 12:e1005676.

An experiment using mice lacking the interferon-α/β receptor inoculated intradermally with DENV revealed that mosquito saliva gland extract (SGE) exacerbates dengue pathogenesis. SGE was shown to increase virulent titers in the skin, boost antibody-enhanced DENV infection of dendritic cells and macrophages in the dermis, and amplify dendritic cell migration to skin-draining lymph nodes.

35. Póvoa TF, Alves AM, Oliveira CA, Nuovo GJ, Chagas VL, Paes MV: The pathology of severe dengue in multiple organs of human fatal cases: histopathology, ultrastructure and virus replication. PLoS One 2014, 9:e83386.

36. Sarathy VY, White M, Li L, Gorder SP, Pyles RB, Campbell GA, Milligan GN, Bourne N, Barrett AD: A lethal murine infection model for dengue virus 3 in AG129 mice deficient in type I and II interferon receptors leads to systemic disease. J Virol 2015, 89:1254-1266.

37. Shresta S, Kyle JL, Robert Beatty P, Harris E: Early activation of natural killer and B cells in response to primary dengue virus infection in A/J mice. Virology 2004, 319:262-273.

38. Bissonnette EY, Rossignol PA, Befus AD: Extracts of mosquito salivary gland inhibit tumour necrosis factor alpha release from mast cells. Parasite Immunol 1993, 15:27-33.

39. Wasserman MA, Singh S, Champagne DE: Saliva of the Yellow Fever mosquito, Aedes aegypti, modulates murine lymphocyte function. Parasite Immunol 2004, 26:295-306.

40. Schneider BS, Soong L, Coffey LL, Stevenson HL, McGee CE, Higgs S: Aedes aegypti saliva alters leukocyte recruitment and cytokine signaling by antigen-presenting cells during West Nile virus infection. PLoS One 2010, 5:e11704.

41. Bizzarro B, Barros MS, Maciel C, Gueroni D, Lino CN, Campopiano J, Kotsyfakis M, Armarante-Mendes GP, Calvo E, Capurro ML et al.: Effects of Aedes aegypti saliva components on dendritic cell and lymphocyte biology. Parasites Vectors 2013, 6:329.

42. Ader DB, Celluzzi C, Blising J, Gilmore L, Gunther V, Peachman KK, Rao M, Barbir D, Sun W, Palmer DR: Modulation of dengue virus infection of dengue cells by Aedes aegypti saliva. Viral Immunol 2004, 17:252-265.

43. Arca B, Lombardo F, Fransciscetti JM, Pham VM, Mestres-Simon M, Andersen JF, Ribeiro JM: An insight into the sialome of the adult female mosquito Aedes albopictus. Insect Biochem Mol Biol 2007, 37:107-127.

44. Almeras L, Fontaine A, Belghazi M, Bourdon S, Boucoumt-Chapeaublanc E, Orlandi-Pradines E, Baragatti M, Corre-Catalin N, Reiter P, Pradines B et al.: Salivary gland protein repertoire from Aedes aegypti mosquitoes. Vector Borne Zoonotic Dis 2010, 10:391-402.

45. Schneider BS, Higgs S: The enhancement of arbovirus transmission and disease by mosquito saliva is associated with modulation of the host immune response. Trans R Soc Trop Med Hyg 2008, 102:400-408.

46. Machain-Williams C, Mammen MP, Zeidner NS, Beatty BJ, Prejni N, Nisalak A, Blair CD: Association of human immune response to Aedes aegypti saliva proteins with dengue disease severity. Parasite Immunol 2012, 34:15-22.

47. Ribeiro JM, Arcà B, Lombardo F, Calvo E, Phan VM, Chandra PK, Wikel SK: An annotated catalogue of salivary gland transcripts in the adult female mosquito, Aedes aegypti. BMC Genomics 2007, 8:6.

48. Conway MJ, Watson AM, Colpitts TM, Dragovic SM, Li Z, Wang P, Felisosa F, Shepherd DT, Ryman KD, Klimstra WB et al.: Mosquito saliva serine protease enhances dissemination of dengue virus into the mammalian host. J Virol 2014, 88:164-175.

Serine protease activity in Aedes aegypti saliva augmented virus infectivity in vitro by proteolyzing extracellular matrix proteins, thereby increasing viral attachment to heparan sulfate proteoglycans and inducing cell migration.

49. Calvo E, Tokumasu F, Marinotti O, Vileille J, Ribeiro JM, Fransciscetti JM: Aegyptin, a novel mosquito salivary gland protein, specifically binds to collagen and prevents its interaction with platelet glycoprotein VI, integrin alpha2beta1, and von Willebrand factor. J Biol Chem 2007, 282:26928-26938.

50. Chagas AC, Ramirez JL, Jasinskaie N, James AA, Ribeiro JM, Marinotti O, Calvo E: Collagen-binding protein, Aegyptin, regulates probing time and blood feeding success in the dengue vector mosquito, Aedes aegypti. Proc Natl Acad Sci U S A 2014, 111:6946-6951.

Transgenic-based, gene-silencing approach elicited a specific and significant reduction of Aegyptin mRNA and protein levels in female salivary glands. The resulting prolonged probing times and reductions in feeding quality and quantity support the conclusion that platelet aggregation inhibition is a vital salivary function and that Aegyptin plays a significant and nonredundant role in successful feeding.

51. Calvo E, Mans BJ, Andersen JF, Ribeiro JM: Function and evolution of a mosquito salivary protein family. J Biol Chem 2006, 281:1935-1942.
52. Sun D, McNicol A, James AA, Peng Z: Expression of functional recombinant mosquito salivary apyrase: a potential therapeutic platelet aggregation inhibitor. Platelets 2006, 17:178-184.

53. Boppana VD, Thangamani S, Adler AJ, Wikel SK: SAAG-4 is a novel mosquito salivary protein that programmes host CD4 T cells to express IL-4. Parasite Immunol 2009, 31:287-295.

54. Lambrechts L, Scott TW, Gubler DJ: Consequences of the expanding global distribution of Aedes albopictus for dengue virus transmission. PLoS Negl Trop Dis 2010, 4:e646.

55. Sim S, Ramirez JL, Dimopoulos G: Dengue virus infection of the Aedes aegypti salivary gland and chemosensory apparatus induces genes that modulate infection and blood-feeding behavior. PLoS Pathog 2012, 8:e1002631.

56. Juhn J, Naeem-Ullah U, Maciel Guedes BA, Majid A, Coleman J, Paolucci Pimenta PF, Akram W, James AA, Marinotti O: Spatial mapping of gene expression in the salivary glands of the dengue vector mosquito, Aedes aegypti. Parasites Vectors 2011, 4:1.